News | March 07, 2023
Evonik partners with AMSilk to manufacture sustainable silk proteins
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
This artificial RNA ligase has higher thermostability than natural RNA ligase
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Subscribe To Our Newsletter & Stay Updated
